JP Morgan Chase
RCKT icon

JP Morgan Chase’s Rocket Pharmaceuticals RCKT Stock Holding History

JP Morgan Chase’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-354,700
Closed -$9.56M – 7686
2024
Q1 		$9.56M Buy
354,700
+171,300
+93% +$4.87M ﹤0.01% 2534
2023
Q4 		$5.5M Buy
+183,400
New +$4.05M ﹤0.01% 2992
2023
Q3 		– Sell
-43,400
Closed -$862K – 7684
2023
Q2 		$862K Buy
+43,400
New +$877K ﹤0.01% 4171

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase's RCKT Position: Q1 2026 in Review

JP Morgan Chase reduced its Rocket Pharmaceuticals (RCKT) stake by 46% in Q1 2026, selling an estimated $2.7M and leaving 796,224 shares worth $2.74M. The position accounts for ﹤0.01% of the portfolio, ranked #3863.

JP Morgan Chase first reported a position in RCKT in Q1 2016 and has held it in 37 quarters since. The position peaked at $35M in Q2 2021. 198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • JP Morgan Chase held 796,224 shares of Rocket Pharmaceuticals worth $2.74M as of Q1 2026.
  • JP Morgan Chase sold 679,400 Rocket Pharmaceuticals shares in Q1 2026, an estimated $2.7M.
  • Rocket Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3863 holding.
  • JP Morgan Chase first reported a position in Rocket Pharmaceuticals in Q1 2016 and has held it in 37 quarters since.
  • JP Morgan Chase's Rocket Pharmaceuticals position peaked at $35M in Q2 2021.
  • 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.